Acquired by Gambro BCT; Name changed to CaridianBCT July 14, 2008; CaridianBCT aquired by Terumo March 2011.
Tokyo Stock Exchange: 4543
Antigenics acquired Aronex Pharmaceuticals in 2001; Name change to Agenus Jan 2011.
Acquired by bioMérieux, Inc. in 2006.
NYSE Euronext: BIM
Formerly EnVivo Pharmaceuticals.
Acquired by Sigma-Aldrich in 1998.
Acquired by Genaissance Pharmaceuticals in 2004; Genaissance Pharmaceuticals acquired by Clinical Data Inc. in October 2005; Clinical Data Inc. Acquired by Forest Laboratories in 2011.
NYSE Euronext: FRX
Subsidiary of Otsuka America.
PrimaCIS was acquired by MedicaLogic in 1999; acquired by GE Medical Systems April 1, 2002.
NYSE Euronext: GE
Formerly Zonagen, Inc.
Sapphire is a biopharmaceutical company committed to developing and commercializing promising compounds that are ready for clinical or pre-clinical testing in oncologic and metabolic disease. The most advanced drug candidate in Sapphire’s pipeline is a small molecule ghrelin agonist. Switzerland-based pharmaceutical group Helsinn has acquired the US-based biopharmaceutical company, Sapphire Therapeutics. Phase II human clinical trials for cancer cachexia.
Acquired by SkillSoft in 2002.
Acquired by PerkinElmer, Inc. in 2006.
NYSE Euronext: PKI
Formerly GeneMedicine, Inc.; merged with Megabios in 1999 and became Valentis.
Formerly ADViSYS; acquired by Inovio Biomedical Corporation in 2009.
NYSE Euronext: INO